- Home
- EQX vs BAX Comparison
EQX vs BAX Comparison
Compare EQX & BAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EQX | BAX |
|---|---|---|
| Founded | 2007 | 1931 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medical/Dental Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9B | 10.0B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | EQX | BAX |
|---|---|---|
| Price | $14.10 | $19.18 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 10 |
| Target Price | $17.00 | ★ $25.67 |
| AVG Volume (30 Days) | ★ 8.9M | 7.7M |
| Earning Date | 02-18-2026 | 02-12-2026 |
| Dividend Yield | N/A | ★ 0.21% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | $2,296,356,000.00 | ★ $11,023,000,000.00 |
| Revenue This Year | $78.98 | $5.20 |
| Revenue Next Year | $29.11 | $2.00 |
| P/E Ratio | $177.47 | ★ N/A |
| Revenue Growth | ★ 85.65 | 3.90 |
| 52 Week Low | $4.95 | $17.40 |
| 52 Week High | $15.10 | $37.74 |
Technical Indicators
Market Signals| Indicator | EQX | BAX |
|---|---|---|
| Relative Strength Index (RSI) | 52.76 | 51.27 |
| Support Level | $13.84 | $18.65 |
| Resistance Level | $14.59 | $19.49 |
| Average True Range (ATR) | 0.59 | 0.42 |
| MACD | -0.11 | 0.08 |
| Stochastic Oscillator | 33.33 | 57.96 |
Price Performance
Historical ComparisonAbout EQX Equinox Gold Corp.
Equinox Gold Corp is a mining company engaged in the operation, acquisition, exploration, and development of mineral properties, with a focus on gold. Equinox Gold has around seven operating gold mines and a clear plan to increase production by advancing the pipeline of growth projects. Geographically, the company operates in the United States, Mexico, and Brazil. The majority of its revenue is generated from Canada.
About BAX Baxter International Inc.
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.